Add the following new claim 12:

12. (new) A method for treating diabetes comprising administering to an individual in need of such treatment an effective amount of an analog according to claim 1 or 3.

Rewrite claims 4-6 and 8 to read as follows. A mark-up of the amended claims is submitted herein as Appendix A.

4. (amended) A peptide analogue as claimed in claim 1 or 3 wherein the substitution or modification is chosen from the group comprising D-amino acid substitutions in 1, 2 and/or 3 positions and/or N terminal glycation, alkylation, acetylation or acylation.

5. (amended) A peptide analogue as claimed in claim 1 or 3 wherein the amino acid in the 2 or 3 position is substituted by lysine, serine, 4-amino butyric, Aib, D-alanine, Sarcosine or Proline.

6. (amended) An analogue as claimed in claim 1 or 3 wherein the N terminus is modified by one of the group of modifications including glycation, alkylation, acetylation or by the addition of an isopropyl group.

8. (amended) A pharmaceutical composition including an analogue as claimed in claim 1 or 3.

Remarks

Claims 1-6 and 8-12 are pending in the application. The dependencies of certain claims have been reduced, to conform to United States practice. Claim 7 has been cancelled and presented as claim 12, in a method of treatment format consistent with United States practice. No new matter has been introduced.

An Abstract is submitted herewith, which is identical to the abstract appearing in the international application.

FINBARR PAUL MARY O'HARTE et al



DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Phone: (215) 988-3312
Fax: (215) 988-2757
Attorney for the Applicants

APEENDIX A: Mark-up of amended claims

4. (amended) A peptide analogue as claimed in [any of the preceding claims] claim 1 or 3 wherein the substitution or modification is chosen from the group comprising D-amino acid substitutions in 1, 2 and/or 3 positions and/or N terminal glycation, alkylation, acetylation or acylation.

5. (amended) A peptide analogue as claimed in [any of the preceding claims] claim 1 or 3 wherein the amino acid in the 2 or 3 position is substituted by lysine, serine, 4-amino butyric, Aib, D-alanine, Sarcosine or Proline.

6. (amended) An analogue as claimed in [any of the preceding claims] claim 1 or 3 wherein the N terminus is modified by one of the group of modifications [include] including glycation, alkylation, acetylation or by the addition of an isopropyl group.

8. (amended) A pharmaceutical composition including an analogue as claimed in [any of the preceding claims] claim 1 or 3.

Abstract

The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42, include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.